Emergent BioSolutions Inc. EBS | NYSE
After Hours
Next Earnings: Aug 11, 2025
Company Overview:
10 Year EBS Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
EBS Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for EBS
Based on past 10-year performance, here are EBS growth metrics:
Share price CAGR of -14.55%
Dividend CAGR of +0%
Using EBS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| EBS (DRIP) | EBS - No DRIP | |
|---|---|---|
| Current Price | $6.93 | $6.93 |
| Start Shares | 1,443.00 | 1,443.00 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,443.00 | 1,443.00 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $1.68 | $6.93 |
| Total Dividends | $0 | $0 |
| Final Value | $2,429 | $10,000 |
NOTE: Above numbers are our estimate based on EBS's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Emergent BioSolutions Inc. (EBS) had its IPO on 2006-11-15, and is trader on NYSE stock exchange.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
EBS website: https://www.emergentbiosolutions.com
